CHICAGO--(BUSINESS WIRE)--An industry-leader in AI-driven digital medicine, physIQ, Inc. will showcase its award-winning pinpointIQTM solution at upcoming healthcare industry events: HIMSS18: physIQ Booth #10613 and ACC.18 Premier Cardiology Exposition: physIQ Booth #2408.
At both events, physIQ will demonstrate pinpointIQ, its end-to-end ambulatory monitoring solution that applies machine learning analytics to continuous patient data streams from wearable sensors. At ACC.18, physIQ will additionally present results from its groundbreaking, VA-sponsored heart failure study – Continuous Wearable Monitoring Analytics Predict Heart Failure Decompensation: The LINK-HF Multi-Center Study – Session 901-14 to be held March 11th from 9:15 to 9:30 a.m. in room 312-A.
“As value-based care models force health systems to rethink the financial risk associated with post-acute populations, wearable sensors and sophisticated analytics offer the opportunity to transform how at-risk patients are cared for,” said Gary Conkright, CEO of physIQ. “In this exciting era of digital medicine, pinpointIQ delivers real-world patient data and analytics to improve care and support clinicians tasked with managing large, complex post-acute populations.”
Delivering Continuous Patient InsightTM
As the first personalized multivariate analytics engine to receive FDA 510k clearance, the pinpointIQ solution collects continuous physiological patient data from wearable biosensors and applies artificial intelligence-based analytics to detect subtle changes in a patient’s vital sign patterns. The continuous and near real-time nature of the solution allows healthcare enterprises to proactively manage care and identify personalized changes that may be a precursor to an acute care event. The data- and device-agnostic physIQ platform can accommodate any Bluetooth-enabled biosensor and has been engineered to be highly scalable and capable of continuously monitoring large patient populations. The care team user interface enables drill-down functionality into physiology data for each patient and at-a-glance visibility across the monitored patient population.
Bio-pharma and medical device manufacturers are capitalizing on unprecedented patient data sets by leveraging the physIQ platform and analytics for clinical trials to accelerate R&D, develop new biomarkers, and validate the safety and efficacy of their products. Unlike patient-reported outcomes alone which are inherently subjective in nature, continuous biosensor data streams and personalized analytics provide a highly efficient means to capture clinical-grade, real-world, objective physiological data and transform it into personalized insight. By virtue of detecting personalized changes from a learned baseline, as well as enabling cross-cohort analysis, life science companies are benefitting from novel and highly differentiated data sets to support their trial endpoints.
“The physIQ platform provides a powerful tool to catalyze the digital transformation, with advanced analytics to decode real-time vital sign data and provide personalized clinical insights never before thought possible,” adds Conkright.
PhysIQ is a company dedicated to enabling proactive care delivery models through pinpointIQTM, its highly scalable cloud-based platform for personalized physiology analytics. Our FDA 510k-cleared data analytics platform is designed to process multiple vital signs from wearable sensors to create a personalized dynamic baseline for each individual. By mapping vital sign relationships this way, physIQ’s analytics detect subtle deviations that may be a precursor to disease exacerbation or change in health. With applications in both healthcare and clinical trial support, physIQ is transforming continuous physiological data into insight for providers, health systems, payers, and pharmaceutical and medical device companies. For more information, please visit www.physiq.com. Follow us on Twitter and LinkedIn.